Document is current
Any future updates will be listed below
-
Authors
Zhou, Yiyang https://orcid.org/0000-0001-8956-3229
Ahearn, Yani P.
Lokugamage, Kumari G.
Morgan, Angelica L.
Alvarado, R. Elias
Estes, Leah K.
Meyers, William M.
McLeland, Alyssa M.
Murray, Jordan T.
Rouse, Joseph R.
Kar, Meenakshi
Suthar, Mehul S. https://orcid.org/0000-0002-2686-8380
Walker, David H.
Johnson, Bryan A. https://orcid.org/0000-0002-8999-1255
Routh, Andrew L. https://orcid.org/0000-0002-2874-5990
Menachery, Vineet D. https://orcid.org/0000-0001-8803-7606
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI153602)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI171413)
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 20 November 2025
First Online: 2 December 2025
Competing interests
: A.L.R. is a co-founder and co-owner of “ClickSeq Technologies LLC.”, a next-generation sequencing service provider of ClickSeq protocols and downstream analyses such as those presented in this manuscript. VDM has filed a patent on the reverse genetic system for SARS-CoV-2. All other authors declare no conflicts of interest.
